Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib | BMC Cancer | Full Text
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer - ScienceDirect
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Ca
Olanib medicine 50mg Olaparib treats ovarian cancer - Price Olanib - INDEX CHINA Medicine
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer? - ScienceDirect
IJMS | Free Full-Text | Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy | HTML
Olanib Tablets (Olaparib), टैबलेट्स - Lancer Health Care, New Delhi | ID: 20611805133
Cancers | Free Full-Text | Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes | HTML
Lynparza Olaparib 150mg at Rs 315000/box | Lynparza | ID: 2487382288
Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines | Anticancer Research
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database - The Lancet Haematology
Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines | Anticancer Research
Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer
Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome - ScienceDirect
Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer
An Overview of PARP Inhibitors for the Treatment of Breast Cancer | SpringerLink
Olaparib | Buy Olaprib 50 mg only $430 || emergencydrug.com
Cancers | Free Full-Text | Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes | HTML
Cancers | Free Full-Text | Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer | HTML
Cancers | Free Full-Text | Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes | HTML
Role of PARP Inhibitors in BRCA-Related Malignancies
